Compelling preclinical study results

Preclinical studies have shown that SBP-101 produces superior anti-tumor activity in human cancer cell lines compared to gemcitabine or nab-paclitaxel, alone or in combination, standard of care chemotherapy drugs used to treat pancreatic cancer.

Sun BioPharma’s novel approach

The Company believes that SBP-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed.  Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life.  Read More
* pancreatic ductal adenocarcinoma

Compound & Clinical Targets

SBP-101

Pancreatic Cancer

Pancreatitis

Leadership

Michael Cullen,<br />MD

Michael Cullen,
MD

President and
Chairman of the Board
Read More
Cliff McCurdy,<br />Ph.D.

Cliff McCurdy,
Ph.D.

Co-Founder,
Chief Executive Officer
Read More
Thomas Neenan,<br />Ph.D.

Thomas Neenan,
Ph.D.

Chief Scientific Officer
 
Read More
John E. Allen<br />Jr.

John E. Allen
Jr.

Chief Business Officer
 

Read More

Suzanne Gagnon,<br />MD

Suzanne Gagnon,
MD

Chief Medical Officer
 
Read More
Ajit Shah,<br />Ph.D.

Ajit Shah,
Ph.D.

VP Pharmacology
 
Read More
Andy Kiorpes,<br />Ph.D.

Andy Kiorpes,
Ph.D.

Toxicology Consultant
 
Read More
Cheryl Baker,<br />Ph.D.

Cheryl Baker,
Ph.D.

Cancer Cellular Biology
Consultant
Read More

Collaborations